Biotecnol Limited is developing the next generation of antibody-based therapeutics for the treatment of diseases in a vast number of therapeutic areas and indications based on its proprietary Tribody™ technology.



Tribody molecules are multi-specific antibody products which utilize the natural in vivo heterodimerization of Fab fragments to form a scaffold, upon which additional proteins can be incorporated. As a result Tribodies are characterized by an unsurpassed versatility; they can incorporate up to three different binders and combine different and novel functions, such as T-cell recruitment and dual targeting, in a single molecule. This new format for T-cell recruiting antibodies has demonstrated superior therapeutic performances both in vitro and in vivo.

> Read More

News & Media

Chiome Bioscience and Biotecnol announce Co-development and Exclusive Option Agreement.

29 January, 2013.  Biotecnol (hereinafter referred to as Biotecnol) and Tokyo-based biotech-venture company, Chiome Bioscience, Inc. (TSE/4583,...

> Read More

Biotecnol and PolyTherics enter into a Research Collaboration for the Development of ‘Tribody’ Antibody Drug Conjugates.

23 October 2012. Biotecnol and PolyTherics Ltd. have entered into a collaboration for the development of multi-specific Tribody Drug Conjugates...

> Read More

Biotecnol sets its US Office at The Commercialization Center for Innovative Technologies (CCIT) in New Jersey.

March 1, 2012 – Biotecnol, Inc. announces that the company has set-up its US office at the Commercialization Center for Innovative...

> Read More